AK
ASHOK KUMAR SHAW Dirigeant
Other
IN IN · SEBI (PIT + SAST)
Browse the full record of transactions filed by ASHOK KUMAR SHAW, Dirigeant. Insider active across 1 companies, notably Gland Pharma Limited. Aggregated, 14 filings have been recorded. The latest transaction was disclosed on 28 June 2022 — Sale. Regulator: SEBI (PIT + SAST). All data is free.
Declarations 14 total
€86,443 2,700 shares @ €32.016
Equity Shares
SEBI:96872c3ae169bce515e2c0fc5c8f1ccdf47ef1ad · 28 Jun 2022
€48,067 1,500 shares @ €32.0448
Equity Shares
SEBI:c7cdc9a89bcb562b4a3fe9ed1d5d4d294bdc7604 · 24 Jun 2022
€49,114 1,600 shares @ €30.6965
Equity Shares
SEBI:bfb01d7145424c9be90de655bc2ae920cfba6d50 · 20 Jun 2022
€70,236 2,200 shares @ €31.9254
Equity Shares
SEBI:506d6b24dfe72c36d8b2a9bfab2ea9182b9ddf4a · 16 Jun 2022
€67,100 2,000 shares @ €33.5502
Equity Shares
SEBI:407f938b34d1151e3a07afe4cdcca45008f9d8ed · 14 Jun 2022
€3,388 100 shares @ €33.8799
Equity Shares
SEBI:9e246c35c2d5657c6ba13752734e2f4fe7c3257d · 8 Jun 2022
€20,311 600 shares @ €33.8521
Equity Shares
SEBI:b5e39180b93e089d4c9787e612d3cc58c2803d98 · 9 Jun 2022
€28,243 4,200 shares @ €6.7246
Equity Shares
SEBI:1d47cac81348d5520585606a5f1de8c66b1321fa · 29 Apr 2022
Ideal exit: 24 Jan 2023 (T+270) €9,727 250 shares @ €38.9082
Equity Shares
SEBI:a361805c63c94e072b0881f843435d79742fcfa5 · 31 Mar 2022
€34,913 750 shares @ €46.5509
Equity Shares
SEBI:0f4c08e928bc49d96089bcffe31d7ef55bdf2afc · 30 Dec 2021
€22,770 500 shares @ €45.5403
Equity Shares
SEBI:bb6beec8ad139dae5af7cb9ad0b3cff2593aa4f3 · 23 Dec 2021
€10,714 250 shares @ €42.8552
Equity Shares
SEBI:6754a699508a92cf76384e82fcd6f3a55491dc96 · 16 Dec 2021
€10,714 250 shares @ €42.8552
Equity Shares
SEBI:3113b9473ccf8585c702124b96873794d4caa723 · 16 Dec 2021
€62,436 1,300 shares @ €48.0275 0.0000% mcap 100.0% of flow
Equity Shares
SEBI:b17475a5033eb0fcb5ce146f8f38d64c7d1d6b64 · 10 Aug 2021
About ASHOK KUMAR SHAW Ashok Kumar Shaw is an executive at Gland Pharma Limited. He is involved in the management of the company and contributes to its development strategy. His expertise is essential for the company's performance.